News & Insights

Double-blind randomised clinical trials A double-blind randomised clinical trial prevents bias when evaluating patient outcomes, validating the research. It is

PSYCH spoke with Angela Allbee, Oregon Psilocybin Services Section Manager at Oregon Health Authority, for The Psychedelics as Medicine Report:

In July, Ann Shulgin passed away following a long battle with lung disease. Alongside late husband Alexander Shulgin, Ann detailed

Earlier this month, the Thai government announced it will develop depression treatments from psilocybin-producing fungi. The World Health Organization estimates

In July, UK-based COMPASS Pathways’ share price surged 40% – far outpacing the market’s rebound. Notable inflection points included the

The World Health Organization recently released its mental health report, which analysed the scale of the mental health crisis and

Last week, the U.S Department of Health and Human Services revealed the government expects both MDMA and psilocybin to be

There are strong signs Europe and North America are about to enter a recession, as sanctions against Russian oil and

Britain’s burgeoning psychedelic healthcare ecosystem includes leading research institutions, drug developers and clinical operations, with ancillary organisations providing essential financial

On Monday, over 100 healthcare professionals in Canada challenged the health minister’s decision to reject their application to access psilocybin.

Access to therapists is critical to the adoption of psychedelic-assisted therapy, and ensuring market access is crucial for the industry

At PSYCH Symposium: London 2022, Kernel’s Chief Technology Officer, Ryan Field, delivered a presentation on the use of the company’s